Atheroprotective effects of HDL: beyond reverse cholesterol transport
- PMID: 18336237
- DOI: 10.2174/138945008783755557
Atheroprotective effects of HDL: beyond reverse cholesterol transport
Abstract
The risk of atherosclerosis is inversely related to circulating levels of high density lipoprotein (HDL) cholesterol. Notably, in large-scale epidemiologic studies, this association is independent of plasma levels of low density lipoprotein cholesterol levels. Pharmacologic agents, such as fibrates and niacin that increase HDL cholesterol levels have been associated with decreased cardiovascular events and beneficial effects on the coronary and carotid arteries. Furthermore, there is evidence that the risk of restenosis following vascular interventions is inversely related to HDL levels. This review considers the available data from mainly murine models on potential mechanisms by which HDL may exert these anti-atherogenic effects, namely through its role in reverse cholesterol transport, its effects on endothelial cells, and its anti-inflammatory/anti-oxidant activities. In addition to discussing a role for HDL in retarding atherosclerosis progression, we will also review how HDL may play a role in promoting regression of atherosclerotic lesions.
Similar articles
-
Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.Drugs. 2003;63(18):1907-45. doi: 10.2165/00003495-200363180-00003. Drugs. 2003. PMID: 12930163 Review.
-
Low high-density lipoprotein cholesterol: current status and future strategies for management.Vasc Health Risk Manag. 2010 Oct 29;6:979-96. doi: 10.2147/VHRM.S5685. Vasc Health Risk Manag. 2010. PMID: 21127701 Free PMC article. Review.
-
High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.Curr Pharm Des. 2010 May;16(13):1480-93. doi: 10.2174/138161210791051013. Curr Pharm Des. 2010. PMID: 20196740 Review.
-
Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action.J Atheroscler Thromb. 2018 Oct 1;25(10):985-993. doi: 10.5551/jat.RV17025. Epub 2018 Aug 27. J Atheroscler Thromb. 2018. PMID: 30146614 Free PMC article. Review.
-
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.Pharmacol Ther. 2006 Sep;111(3):893-908. doi: 10.1016/j.pharmthera.2006.02.003. Epub 2006 Mar 29. Pharmacol Ther. 2006. PMID: 16574234 Review.
Cited by
-
An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.Exp Clin Cardiol. 2011 Fall;16(3):77-86. Exp Clin Cardiol. 2011. PMID: 22065938 Free PMC article.
-
Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis.J Inflamm Res. 2011;4:83-92. doi: 10.2147/JIR.S12983. Epub 2011 Jun 2. J Inflamm Res. 2011. PMID: 22096372 Free PMC article.
-
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells.Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7166-71. doi: 10.1073/pnas.1016086108. Epub 2011 Apr 11. Proc Natl Acad Sci U S A. 2011. PMID: 21482781 Free PMC article.
-
ATP Synthase β-Chain Overexpression in SR-BI Knockout Mice Increases HDL Uptake and Reduces Plasma HDL Level.Int J Endocrinol. 2014;2014:356432. doi: 10.1155/2014/356432. Epub 2014 Jul 10. Int J Endocrinol. 2014. PMID: 25114680 Free PMC article.
-
Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.J Natl Med Assoc. 2011 Jun;103(6):524-33. doi: 10.1016/s0027-9684(15)30368-0. J Natl Med Assoc. 2011. PMID: 21830637 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical